California Stem Cell Agency Invests $16.4 Million to Test Great New Ideas Targeting Cancer, Vision Loss and Parkinson’s Disease.
Every life-saving therapy or advance in medicine begins with a scientist posing a simple question, “I wonder if…?” Today the governing Board of the California Institute for Regenerative Medicine (CIRM) invested more than $16.4 million to help researchers find answers to questions that could one day lead to new therapies for leukemia, respiratory problems, and a devastating skin disease that affects children.
Every life-saving therapy or advance in medicine begins with a scientist posing a simple question, “I wonder if…?” Today the governing Board of the California Institute for Regenerative Medicine (CIRM) invested more than $16.4 million to help researchers find answers to questions that could one day lead to new therapies for leukemia, respiratory problems, and a devastating skin disease that affects children.
The CIRM Board approved $3.02 million in funding for 14 projects in our Discovery Inception program. These are great new ideas that could have a big impact on the field of stem cell research but need some funding to help test those ideas and see if they work. The Board also invested $13.4 million in funding for three projects at the Translation stage. These are programs that have already shown promise in early stage research. Under this award they can now do the work to advance it to the next level of development.
“This research is critically important in advancing our knowledge of stem cells and are the foundation for future therapeutic candidates and treatments,” says Maria Millan, M.D., President and CEO of CIRM. “Exploring and testing new ideas increases the chances of finding treatments for patients with unmet medical needs. Without CIRM’s support many of these projects might never get off the ground. That’s why our ability to fund research, particularly at the earliest stage, is so important to the field as a whole.”
The Translation stage projects include:
- $5.56 million to Anthony Oro at Stanford to test a stem cell therapy to help people with a form of Epidermolysis bullosa, a painful, blistering skin disease that leaves patients with wounds that won’t heal.
- $5.15 million to Dan Kaufman at UC San Diego to produce natural killer (NK) cells from embryonic stem cells and see if they can help people with acute myelogenous leukemia (AML) who are not responding to treatment.
- $2.7 million to Catriona Jamieson at UC San Diego to test a novel therapeutic approach targeting cancer stem cells in AML. These cells are believed to be the cause of the high relapse rate in AML and other cancers.
The Board also approved 14 projects in the Discovery Inception program, including one targeting Parkinson’s disease. The project, by Zenobia Therapeutics, uses induced pluripotent stem cells (iPSCs) that have been turned into dopaminergic neurons – the kind of brain cell that is dysfunctional in Parkinson’s disease. These IPSCs will then be used to screen drugs to see if any hold potential as a therapy for Parkinson’s disease.
David Higgins, Ph.D., a patient advocate member for Parkinson’s on the CIRM Board, said there is a real need for this research: “I’m a fourth generation Parkinson’s patient and I’m taking the same medicine that my grandmother took. They work but not for everyone and not for long. People with Parkinson’s need new treatment options and we need them now. That’s why this project is worth supporting. It has the potential to identify some promising candidates that might one day lead to new treatments.”
“We never know where the next great discovery or breakthrough in stem cell research is going to come from,” says Dr. Millan. “What we do know is that if we don’t fund these intriguing ideas and promising projects then nothing will happen. And we don’t just provide money, we also provide support and guidance to the researchers when needed. We want to do everything we can to ensure all these projects reach their full potential.
ارسال به دوستان